沃森生物(300142.SZ):子公司擬向銀行申請綜合授信及流動資金貸款
格隆匯 7 月 27日丨沃森生物(300142.SZ)公佈,公司於2020年7月27日召開第四屆董事會第十一次會議,審議通過了《關於子公司向銀行申請綜合授信及流動資金貸款的議案》。公司控股子公司玉溪沃森生物技術有限公司(“玉溪沃森”)根據業務發展需要,擬向雲南紅塔銀行股份有限公司(“紅塔銀行”)、中國建設銀行股份有限公司玉溪市分行(“建設銀行玉溪市分行”)申請綜合授信及流動資金貸款。
公司控股子公司玉溪沃森根據業務發展需要,為保證生產經營資金需求,拓寬融資渠道,擬分別向紅塔銀行、建設銀行玉溪市分行申請綜合授信及流動資金貸款人民幣2億元、3億元,授信及貸款期限均為1年,用途為玉溪沃森日常生產經營所需的資金週轉。
上述授信及流動資金貸款為信用方式,不涉及向銀行提供擔保,不涉及以任何股權、實物、房地產及無形資產抵押、質押。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.